AN1's Principal Activity is the advangen Limited (Advangen):- During FY2019 Advangen continued with the development and sale of over-the-counter (OTC) and cosmetic products for hair loss and anti-aging hair care using proprietary FGF5 inhibitor technology
Last (Price) | |
Change | 0.00 (0.00) |
Bid / Ask | - |
Volume | |
Volume (4w avg) | |
Turnover | |
Open | |
Day Range | - |
VWAP | |
Prev Close | |
Last Trade |
1 Week | |
1 Month | |
2022 YTD | |
1 Year | |
vs Sector (1yr) | - |
vs ASX 200 (1yr) | -59.56% |
Date | Heading | Pages | File Size | Time |
---|---|---|---|---|
Anagenics Limited (AN1, formerly Cellmid Limited) is an Australian life sciences accelerator for indication of multiple diseases. It operates mainly through its wholly owned subsidiaries that develop and market innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company holds global intellectual properties relating to novel targets midkine and FGF5.
Incorporated Medical Therapies Limited was incorporated on 8 October 2004 in New South Wales. Code changed to Cellmid Limited (CDY) on 19/11/2009.
Head Office | Sydney NSW 2000 |
Website | www.cellmid.com.au |
Registry | Automic Group |
Auditor | Pitcher Partners |
Date Listed | 9 Dec 2005 |
No calendar entries available.
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
AN1 directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
The current holdings of AN1 directors.
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
Name | Last Notice | Total Shares | Shares Held (%) |
---|---|---|---|
Dennis Keith Eck | 16/08/2021 | 18,147,625 | 9.68 |
HGL Limited | 19/01/2022 | 37,759,433 | 17.08 |
12 month transaction history compiled from ASX announcements.
Date | Name | Bought | Previous % | New % |
---|---|---|---|---|
19-01-22 | HGL Limited | 2,601,477 | 15.97 | 17.08 |
02-11-21 | HGL Limited | 35,157,956 | -- | 15.97 |
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
Date | Close | Change | %Chg | Open | High | Low | Volume | Turnover |
---|---|---|---|---|---|---|---|---|
Year | Closing Price | Last Trade |
---|---|---|
No Financial Year End data available |
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.